These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 20857493)
1. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Mego M; De Giorgi U; Dawood S; Wang X; Valero V; Andreopoulou E; Handy B; Ueno NT; Reuben JM; Cristofanilli M Int J Cancer; 2011 Jul; 129(2):417-23. PubMed ID: 20857493 [TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255 [TBL] [Abstract][Full Text] [Related]
3. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845 [TBL] [Abstract][Full Text] [Related]
6. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083 [TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success. Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230 [TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327 [TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells in newly diagnosed inflammatory breast cancer. Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients. Wong NS; Kahn HJ; Zhang L; Oldfield S; Yang LY; Marks A; Trudeau ME Breast Cancer Res Treat; 2006 Sep; 99(1):63-9. PubMed ID: 16541316 [TBL] [Abstract][Full Text] [Related]
11. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer. Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482 [TBL] [Abstract][Full Text] [Related]
12. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134 [TBL] [Abstract][Full Text] [Related]
13. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140 [TBL] [Abstract][Full Text] [Related]
14. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903 [TBL] [Abstract][Full Text] [Related]
15. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells before and during follow-up after breast cancer surgery. van Dalum G; van der Stam GJ; Tibbe AG; Franken B; Mastboom WJ; Vermes I; de Groot MR; Terstappen LW Int J Oncol; 2015 Jan; 46(1):407-13. PubMed ID: 25339612 [TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286 [TBL] [Abstract][Full Text] [Related]
19. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. De Giorgi U; Mego M; Scarpi E; Giuliano M; Giordano A; Reuben JM; Valero V; Ueno NT; Hortobagyi GN; Cristofanilli M Clin Breast Cancer; 2012 Aug; 12(4):264-9. PubMed ID: 22591634 [TBL] [Abstract][Full Text] [Related]
20. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]